EVOK - Evoke Pharma receives patent for Gimoti to treat moderate to severe gastroparesis

• Evoke Pharma ( NASDAQ: EVOK ) is trading 7.1% higher after it received U.S. patent for Treatment of moderate and severe gastroparesis for Gimoti.
• This patent expires in 2038 and covers the methods for treating moderate-to-severe gastroparesis with metoclopramide via an intranasal route of administration.
• "We are thrilled to add this new patent to our IP estate, primarily focused on ensuring the long-term availability of our novel product, GIMOTI, to help patients and healthcare providers in need of a revolutionary solution to treat diabetic gastroparesis symptoms," the company said.

For further details see: